Lind Global Fund II discloses 6.62% Tenax (TENX) position through capped warrants

Rhea-AI Filing Summary

Lind Global Fund II LP and related reporting persons disclose a passive stake in Tenax Therapeutics, Inc. They report beneficial ownership of 442,480 warrants to purchase common stock, representing 6.62% of Tenax’s common stock. The warrants are subject to a 9.9% beneficial ownership cap on exercise.

Lind Global Partners II LLC, as general partner of Lind Global Fund II LP, and Jeff Easton, as managing member of Lind Global Partners II LLC, may each be deemed to have sole voting and dispositive power over these securities. The reporting persons certify the holdings are not for the purpose of changing or influencing control of Tenax.

Insights

Equity ownership and securities disclosure analyst

Passive holder reports 6.62% Tenax stake via capped warrants.

The filing shows Lind Global Fund II LP and its affiliates beneficially owning 442,480 warrants linked to Tenax Therapeutics common stock, equating to 6.62% of the class. These are derivative securities, not currently outstanding shares, but they count toward ownership under SEC rules.

The warrants cannot be exercised if doing so would push the reporting persons’ beneficial ownership above 9.9%, limiting potential concentration. The group also certifies a passive intent, stating the holdings are not for changing or influencing control. This looks like a standard institutional position disclosure rather than a control transaction.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 3)

TENAX THERAPEUTICS, INC.

(Name of Issuer)

Common Stock, par value $0.0001 per share

(Title of Class of Securities)

88032L605

(CUSIP Number)

12/31/2025

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. 88032L605

1

Names of Reporting Persons

Lind Global Fund II LP

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 442,480.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 442,480.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

442,480.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

6.62 %

12

Type of Reporting Person (See Instructions)

PN

Comment for Type of Reporting Person: The reporting person's ownership consists of 442,480 warrants to purchase shares of common stock (the "Warrants"). Such Warrants may not be exercised if, following such exercise, the reporting person's beneficial ownership would exceed 9.9%.

SCHEDULE 13G

CUSIP No. 88032L605

1

Names of Reporting Persons

Lind Global Partners II LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 442,480.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 442,480.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

442,480.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

6.62 %

12

Type of Reporting Person (See Instructions)

OO

Comment for Type of Reporting Person: The reporting person's ownership consists of 442,480 Warrants. Such Warrants may not be exercised if, following such exercise, the reporting person's beneficial ownership would exceed 9.9%.

SCHEDULE 13G

CUSIP No. 88032L605

1

Names of Reporting Persons

EASTON JEFF

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 442,480.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 442,480.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

442,480.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

6.62 %

12

Type of Reporting Person (See Instructions)

IN

Comment for Type of Reporting Person: The reporting person's ownership consists of 442,480 Warrants. Such Warrants may not be exercised if, following such exercise, the reporting person's beneficial ownership would exceed 9.9%.

SCHEDULE 13G

Item 1.
(a)	Name of issuer: TENAX THERAPEUTICS, INC.
(b)	Address of issuer's principal executive offices: 101 Glen Lennox Drive, Suite 300, Chapel Hill, North Carolina, 27517
Item 2.
(a)	Name of person filing: This statement is filed by the following entities and individuals (collectively, referred to as the "Reporting Persons"): o Lind Global Fund II LP, a Delaware limited partnership; o Lind Global Partners II LLC, a Delaware limited liability company; and o Jeff Easton, an individual and a citizen of the United States of America. Lind Global Partners II LLC, the general partner of Lind Global Fund II LP, may be deemed to have sole voting and dispositive power with respect to the shares held by Lind Global Fund II LP. Jeff Easton, the managing member of Lind Global Partners II LLC, may be deemed to have sole voting and dispositive power with respect to the shares held by Lind Global Fund II LP.
(b)	Address or principal business office or, if none, residence: The address of the principal business office for each of the Reporting Persons is: 444 Madison Ave, Floor 41 New York, NY 10022
(c)	Citizenship: See Row 4 of cover page for each Reporting Person.
(d)	Title of class of securities: Common Stock, par value $0.0001 per share
(e)	CUSIP No.: 88032L605
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: See Row 9 of cover page for each Reporting Person.
(b)	Percent of class: See Row 11 of cover page for each Reporting Person.
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: See Row 5 of cover page for each Reporting Person.
	(ii) Shared power to vote or to direct the vote: See Row 6 of cover page for each Reporting Person.
	(iii) Sole power to dispose or to direct the disposition of: See Row 7 of cover page for each Reporting Person.
	(iv) Shared power to dispose or to direct the disposition of: See Row 8 of cover page for each Reporting Person.
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Lind Global Fund II LP

Signature:	By: Lind Global Partners II LLC, its General Partner, By: /s/ Jeff Easton
Name/Title:	Jeff Easton, Managing Member
Date:	02/17/2026

Lind Global Partners II LLC

Signature:	/s/ Jeff Easton
Name/Title:	Jeff Easton, Managing Member
Date:	02/17/2026

EASTON JEFF

Signature:	/s/ Jeff Easton
Name/Title:	Jeff Easton
Date:	02/17/2025

FAQ

What stake in Tenax Therapeutics (TENX) is reported in this Schedule 13G/A?

The reporting persons disclose beneficial ownership of 442,480 warrants tied to Tenax Therapeutics common stock, representing 6.62% of the outstanding common shares. This reflects a significant institutional position exceeding the 5% reporting threshold for passive investors.

Who are the reporting persons in the Tenax Therapeutics (TENX) Schedule 13G/A?

The filing lists Lind Global Fund II LP, Lind Global Partners II LLC, and Jeff Easton as the reporting persons. Lind Global Partners II LLC is the fund’s general partner, and Jeff Easton is its managing member, giving them deemed voting and dispositive power over the securities.

What type of Tenax Therapeutics (TENX) securities are held by the reporting persons?

The reported beneficial ownership consists of 442,480 warrants to purchase Tenax Therapeutics common stock. These derivative securities give the right to acquire common shares but include contractual limits on exercise to control overall beneficial ownership levels.

What percentage of Tenax Therapeutics (TENX) does the 442,480 warrants represent?

The 442,480 warrants are reported as representing 6.62% of Tenax Therapeutics’ common stock. This percentage is calculated under SEC beneficial ownership rules and reflects the size of the position relative to the company’s outstanding common shares.

Is there a cap on how much Tenax Therapeutics (TENX) the reporting persons can beneficially own?

Yes. The warrants may not be exercised if, after exercise, the reporting persons’ beneficial ownership would exceed 9.9% of Tenax’s common stock. This cap helps prevent the investors from crossing a higher ownership threshold through warrant exercises.

Do the reporting persons seek to influence control of Tenax Therapeutics (TENX)?

The filing includes a certification that the securities were not acquired and are not held for the purpose of changing or influencing control of Tenax. They are reported under a passive Schedule 13G framework rather than an activist or control-oriented Schedule 13D.